ARWRArrowhead Pharmaceuticals Inc.
Compact View
Earnings Recap
• Reported GAAP EPS of -$0.93 down -133.45% YoY • Reported revenue of $73.74M down -86.41% YoY • Arrowhead Pharmaceuticals Inc. expects to receive the second installment of an annual fee of up to $50M from Sarepta over the 12 months from March 31, 2026. Additionally, Arrowhead Pharmaceuticals Inc. is eligible for up to $975M in milestone payments from Madrigal.
Bullish
Arrowhead Pharmaceuticals Inc. secured key REDEMPLO approvals and Breakthrough Therapy designation, bolstered its balance sheet with $930M from offerings, and expanded its pipeline through new licensing agreements with Novartis and Madrigal.
Bearish
Arrowhead Pharmaceuticals Inc. experienced a net loss of $132.7M for the quarter, driven by significantly increased R&D and SG&A expenses. Sarepta's step-in right also reduced future variable consideration for certain programs.